Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2006 March; 7(1): E38–E42.
Published online 2005 September 22. doi:  10.1208/pt070106
PMCID: PMC2750713

In vivo characterization of monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: A technical note

Summary and Conclusions

The present work aimed to characterize transdermal drug delivery systems of pinacidil monohydrate in vivo by monitoring the effect of the TDDS on blood pressure of methyl prednisolone acetate induced hypertensive rats. The blood pressure of rats was measured using a noninvasive rat BP instrument based on cuff tail technique. A significant fall in rat BP (P<.01) was observed in treatment of hypertensive rats with all the formulations, which was maintained for 48 hours. Interformulation comparison revealed that formulation B-4 was the most effective with 37.96% reduction in BP (160.33±4.96 vs 99.44±4.46 mmHg). It was concluded that a single patch application of pinacidil TDDS (B-4) can effectively control hypertension in rats for 2 days. The system holds promise for clinical studies.

Keywords: hypertension, transdermal drug delivery system, methylprednisolone acetate, rat, pinacidil

Full Text

The Full Text of this article is available as a PDF (97K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Ishii R, Tagawa T, Ishida T, Naruse T. Antihypertensive effects of a new TDS of clonidine in genetic and experimental rats. Arzneimittelforschung. 1996;46:261–268. [PubMed]
2. Corbo M, Liu JC, Chien YW. Transdermal controlled delivery of propranolol from a multilaminate adhesive device. Pharm Res. 1989;6:753–758. doi: 10.1023/A:1015967329033. [PubMed] [Cross Ref]
3. Kommuru TR, Khan MA, Reddy TK. Effect of chiral enhancers on the permeability of optically active and racemic metoprolol across hairless mouse skin. Chirality. 1999;11:536–540. doi: 10.1002/(SICI)1520-636X(1999)11:7<536::AID-CHIR4>3.0.CO;2-H. [PubMed] [Cross Ref]
4. Aqil M, Sultana Y, Ali A. Monolithic matrix type transdermal drug delivery systems of metoprolol tartrate: in-vitro characterization. Acta Pharm. 2003;53:119–126. [PubMed]
5. Spieker C, Vetter H, Liedtke R, Zidek W, Vetter W. Transdermal beta-blocker therapy in essential hypertension. Am J Hypertens. 1988;1:199S–200S. [PubMed]
6. Shah HS, Tojo K, Chien YW. Transdermal controlled delivery of verapamil: characterization of in vitro skin permeation. Int J Pharm. 1992;86:167–173. doi: 10.1016/0378-5173(92)90194-7. [Cross Ref]
7. Dubey BK. Lypophilzed aqueous-based polymer matrices for transdermal delivery of captopril. J Dermatol Sci. 1995;10:191–195. doi: 10.1016/0923-1811(95)00403-F. [PubMed] [Cross Ref]
8. Rao PR, Diwan PV. Formulation and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration. Drug Dev Ind Pharm. 1998;24:327–336. doi: 10.3109/03639049809085627. [PubMed] [Cross Ref]
9. Thacharodi D, Rao KP. Transdermal absorption of nifedipine from microemulsions of lipophillic skin penetration enhancers. Int J Pharm. 1994;111:235–240. doi: 10.1016/0378-5173(94)90346-8. [Cross Ref]
10. Aqil M, Ali A. Effect of penetration enhancers on transdermal delivery of pinacidil monohydrate. J Sci Pharm. 2002;3:68–71.
11. McBurney A, Farrow PR, Ainsworth S, Ward JW. Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-N-oxide following iv and oral administration in healthy volunteers. Br J Clin Pharmacol. 1985;19:91–94. [PMC free article] [PubMed]
12. Dollery C. Pinacidil Monohydrate (monograph) New York, NY: Churchill Livingstone; 1991. pp. 115–118.
13. Aqil M, Ali A. Monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: in-vitro characterization. Eur J Pharm Biopharm. 2002;54:161–164. doi: 10.1016/S0939-6411(02)00059-0. [PubMed] [Cross Ref]
14. Krakoff LR, Selvadurai R, Sytter E. Effect of methylprednisolone upon arterial pressure and the renin angiotensin system in the rat. Am J Physiol. 1975;228:613–617. [PubMed]
15. Plotz C, Knowlton A, Ragan C. The nature and history of Cushing’s syndrome. Am J Med. 1952;13:597–611. doi: 10.1016/0002-9343(52)90027-2. [PubMed] [Cross Ref]
16. Soffer LJ, Iannaccone A, Gabrilove JL. Cushing’s syndrome: a study of 50 patients. Am J Med. 1961;30:129–134. doi: 10.1016/0002-9343(61)90069-9. [Cross Ref]
17. David DS, Grieco MH, Cushman P. Adrenal glucocorticoids after 20 years: a review of their clinically relevant consequences. J Chronic Dis. 1970;22:637–648. doi: 10.1016/0021-9681(70)90078-0. [PubMed] [Cross Ref]
18. Ragan C. Corticotrophin, cortisone and related steroids in clinical medicine practical considerations. Bull-N. Acad Med. 1973;29:355–364. [PubMed]
19. Kotiyan PN, Vavia PR. Eudragits: role as crystallization inhibitors in drug-in-adhesive transdermal systems of estradiol. Eur J Pharm Biopharm. 2001;52:173–180. doi: 10.1016/S0939-6411(01)00174-6. [PubMed] [Cross Ref]
20. Rao PR, Reddy MN, Ramakrishna S, Diwan PV. Comparative in vivo evaluation of propranolol hydrochloride after oral and transdermal administration in rabbits. Eur J Pharm Biopharm. 2003;56:81–85. doi: 10.1016/S0939-6411(03)00038-9. [PubMed] [Cross Ref]
21. Guyot M, Fawaz F. Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol. Int J Pharm. 2000;204:171–182. doi: 10.1016/S0378-5173(00)00494-4. [PubMed] [Cross Ref]
22. Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulasion for topical delivery of triptolide. Eur J Pharm Biopharm. 2003;56:189–196. doi: 10.1016/S0939-6411(03)00067-5. [PubMed] [Cross Ref]
23. Yoneto K, Ghanem AH, Higuchi WI, Peck KD, Li SK. Mechanistic studies of the 1-alkyl-2-pyrrolidones as skin permeation enhancers. J Pharm Sci. 1995;84:312–317. doi: 10.1002/jps.2600840310. [PubMed] [Cross Ref]
24. Yoneto K, Li SK, Higuchi WI, Shimabayashi S. Influence of the permeation enhancers 1-alkyl-2-pyrrolidones on permeant partitioning into the stratum corneum. J Pharm Sci. 1998;87:209–214. doi: 10.1021/js970190k. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists